表观扩散系数在乳腺癌肝转移早期疗效评价中的进一步探究

发布时间：2018-04-26 09:06

  本文选题：乳腺癌肝转移 + 表观扩散系数　； 参考：《临床放射学杂志》2017年02期

【摘要】：目的应用表观扩散系数(ADC)早期评价乳腺癌肝转移(BCLMs)化疗效果。方法搜集19例(共42个转移灶)乳腺癌肝转移患者资料,10例单用蒽环类治疗,9例采用蒽环联合紫衫类联合治疗。于化疗前3~4天,化疗后1周,化疗后2周及化疗后1个月行MRI平扫及扩散加权成像(DWI),并测定ADC值。采用实体瘤疗效评价标准(RECIST)于化疗4周后划分有效组与无效组。结果在42个转移灶中,有效组有11个,无效组共31个,有效组化疗前后ADC值分别为(0.9±0.16)×10~(-3)mm~2/s,(1.05±0.12)×10~(-3)mm~2/s,(1.26±0.12)×10~(-3)mm~2/s,(1.33±0.87)×10~(-3)mm~2/s;化疗前有效组与无效组的ADC值分别为(0.9±0.16)×10~(-3)mm~2/s,(1.09±0.24)×10~(-3)mm~2/s,F=1.790,P0.05。绘制ROC曲线,化疗后2周,曲线下面积为0.782其可信区间为64.5%~91.8%,具有较高的临床诊断价值,取ADC=1.14×10~(-3)mm~2/s作为判断化疗有效与否的临界点。结论 ADC可于化疗后2周定量判断BCLMs疗效。
[Abstract]:Objective to evaluate the effect of BCLMs chemotherapy with apparent diffusion coefficient (ADCC) in early stage. Methods 19 cases (42 metastatic foci) of breast cancer with liver metastasis were collected. 10 cases were treated with anthracycline alone and 9 cases were treated with anthracycline combined with purpura. MRI plain scan and diffusion-weighted imaging (DWI) were performed 3 days before chemotherapy, 1 week after chemotherapy, 2 weeks after chemotherapy and 1 month after chemotherapy. ADC values were measured. Patients with solid tumor were divided into effective group and ineffective group 4 weeks after chemotherapy according to the criteria for evaluating the curative effect of solid tumor (RECIST). 缁撴灉鍦，

本文编号：1805363